Simultaneous determination of serum galectin-3 and -4 levels detects metastases in colorectal cancer patients

Cellular Oncology

Volumn 36, Issue 1, 2013, Pages 9-13

  Barrow, Hannah ^a   Rhodes, Jonathan M ^a   Yu, Lu Gang ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Colorectal cancer; Galectin 3; Galectin 4; Metastasis

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; GALECTIN 1; GALECTIN 2; GALECTIN 3; GALECTIN 4; GALECTIN 8;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CANCER TISSUE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DETERMINATION; SENSITIVITY AND SPECIFICITY; SERUM;

ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GALECTIN 3; GALECTIN 4; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 84877068117     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-012-0109-1     Document Type: Article

References (19)

1. P.D. Sasieni, J. Shelton, N. Ormiston-Smith et al., What is the lifetime risk of developing cancer?: the effect of adjusting for multiple primaries. Br. J. Cancer 105(3), 460-465 (2011)
2. G. Christofori, New signals from the invasive front. Nature 441(7092), 444-450 (2006)
3. H. Barrow, X. Guo, H.H. Wandall et al., Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin. Cancer Res. 17(22), 7035-7046 (2011)
4. S. Saussez, F. Lorfevre, T. Lequeux et al., The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol. 44(1), 86-93 (2008)
5. S. Saussez, D. Glinoer, G. Chantrain et al., Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid 18(7), 705-712 (2008)
6. M. Sakaki, N. Oka, R. Nakanishi et al., Serum level of galectin-3 in human bladder cancer. J. Med. Investig. 55(1-2), 127-132 (2008)
7. I. Iurisci, N. Tinari, C. Natoli et al., Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin. Cancer Res. 6(4), 1389-1393 (2000)
8. S. Senapati, P. Chaturvedi, W.G. Chaney et al., Novel interaction of MUC4 and galectin: potential pathobiological implications for metastasis in lethal pancreatic cancer. Clin. Cancer Res. 17(2), 267-274 (2011)
9. P. Vereecken, A. Awada, S. Suciu et al., Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on cancer stage III and stage IV melanoma patients. Melanoma Res. 19(5), 316-320 (2009)
10. L.G. Yu, Circulating galectin-3 in the bloodstream: an emerging promoter of cancer metastasis. World J. Gastrointest. Oncol. 2(4), 177-180 (2010)
11. Q. Zhao, X. Guo, G.B. Nash et al., Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. Cancer Res. 69(17), 6799-6806 (2009)
12. A.U. Newlaczyl, L.G. Yu, Galectin-3 - a jack-of-all-trades in cancer. Cancer Lett. 313(2), 123-128 (2011)
13. L.G. Yu, N. Andrews, Q. Zhao et al., Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J. Biol. Chem. 282(1), 773-781 (2007)
14. Q. Zhao, M. Barclay, J. Hilkens et al., Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Mol. Cancer 9, 154 (2010)
15. M. Watanabe, I. Takemasa, N. Kaneko et al., Clinical significance of circulating galectins as colorectal cancer markers. Oncol. Rep. 25(5), 1217-1226 (2011)
16. H. Barrow, J.M. Rhodes, L.-G. Yu, The role of galectins in colorectal cancer progression. Int. J. Cancer 129, 1-8 (2011)
17. S.E. Baldus, F.G. Hanisch, G.M. Kotlarek et al., Coexpression of MUC1 mucin peptide core and the Thomsen-Friedenreich antigen in colorectal neoplasms. Cancer 82(6), 1019-1027 (1998)
18. R. Singh, B.J. Campbell, L.G. Yu et al., Cell surface-expressed Thomsen-Friedenreich antigen in colon cancer is predominantly carried on high molecular weight splice variants of CD44. Glycobiology 11(7), 587-592 (2001)
19. D.N. Cooper, S.H. Barondes, God must love galectins; he made so many of them. Glycobiology 9(10), 979-984 (1999)